BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allografts, announced that its management will present at the 16th Annual LD Micro Invitational in Los Angeles, CA. The presentation is scheduled for Monday, May 18, 2026, at 1:30 PM ET. This event provides BioStem with a platform to communicate its strategic direction and technological advancements to a targeted audience of investors and industry professionals.
BioStem’s focus on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue sets it apart in the regenerative medicine field. The company leverages proprietary processing technologies, including BioRetain®, CryoTek®, and SteriTek®, which are designed to preserve the natural properties of tissues for clinical use. These technologies are critical for ensuring the efficacy and safety of allografts used across various medical specialties.
The company’s quality management system has been reviewed and accredited by the American Association of Tissue Banks (AATB), and its procedures comply with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). This accreditation underscores BioStem’s commitment to maintaining high standards in tissue processing and manufacturing.
BioStem’s product portfolio includes brands such as Neox®, Clarix®, VENDAJE®, and American Amnion™. These products are used by clinicians in applications ranging from wound care to surgical reconstruction, addressing significant unmet needs in tissue repair and regeneration.
The LD Micro Invitational is a key event for emerging growth companies, offering exposure to institutional and retail investors. For BioStem, this presentation is an opportunity to highlight its commercial progress, clinical research initiatives, and national footprint. The company’s investor relations efforts are supported by Gilmartin Group, with Philip Trip Taylor serving as the contact. Public relations are managed by Relevance, with Jennifer Horton as the point of contact.
Investors and interested parties can access live and archived webcasts of the presentation on the investors section of the company’s website at ir.biostemtechnologies.com. Additionally, the latest news and updates about BioStem are available in the company’s newsroom at https://tinyurl.com/bsemnewsroom.
This announcement is significant for the regenerative medicine industry as BioStem continues to advance allograft technologies that could improve patient outcomes. The company’s participation in the LD Micro Invitational signals its active engagement with the investment community, which may drive further interest in its stock and research initiatives. For leaders in business and technology, BioStem’s progress represents a convergence of biomedical innovation and commercial strategy, with potential implications for the future of tissue engineering and regenerative therapies.
